Product Name: Balixafortide
Form: TFA salt
CAS No: 1051366-32-5
Molar Mass: 1864.14
Chemical Formula: C84H118N24O21S2
Synonyms: POL6326
Storage: Store at -20℃
Sequence: Cyclo(ACSA-{D-Pro}-{Dab}-RYCYQK-{D-Pro}-PYH)
Target: CXCR4
Application:
Balixafortide (CAS: 1051366-32-5) is a synthetic peptide-based antagonist of the CXCR4 receptor, a chemokine receptor involved in cell migration, homing, and survival. CXCR4 is overexpressed in various cancers, including breast cancer, prostate cancer, and certain hematological malignancies, where it plays a role in tumor progression, metastasis, and treatment resistance. Balixafortide functions by competitively binding to CXCR4, thereby blocking the interaction between CXCR4 and its ligand, CXCL12 (also known as stromal cell-derived factor 1, SDF-1). This blockade disrupts signaling pathways critical for tumor cell migration, invasion, and survival in the tumor microenvironment. In pharmaceutical chemistry, balixafortide's targeted antagonism of CXCR4 represents a promising approach to cancer therapy, offering a specific and effective means of inhibiting tumor progression and metastasis. Clinical trials are underway to evaluate its safety, efficacy, and therapeutic potential in different cancer types, with the goal of providing new treatment options for patients with advanced or metastatic disease.
Current Research:
Balixafortide is a novel investigational peptide that functions as a selective antagonist of CXCR4, a receptor that plays a pivotal role in the migration and homing of immune cells, particularly T cells, B cells, and hematopoietic stem cells. This peptide is being explored for its therapeutic potential in cancer immunotherapy and hematological disorders, where the modulation of the immune system is crucial for effective treatment. By targeting the CXCR4 receptor, Balixafortide has shown promise in enhancing tumor-specific immune responses, improving hematopoietic stem cell mobilization, and modulating immune cell trafficking, which are key aspects of both cancer treatment and immune system regulation.
Mechanism of Action
Balixafortide works by specifically blocking the CXCR4 receptor, which is a chemokine receptor involved in the movement and migration of immune cells toward sites of inflammation, injury, or cancer. CXCR4, when activated by its ligand stromal cell-derived factor 1 (SDF-1), plays a critical role in maintaining the homing of immune cells to lymphoid tissues and tumor microenvironments. In cancer, CXCR4 has been implicated in promoting tumor metastasis and immune evasion, as well as facilitating the interaction of cancer cells with the tumor stroma. By blocking this pathway, Balixafortide prevents the recruitment of immune-suppressive cells into the tumor site, which can enhance the effectiveness of cancer therapies and improve immune system activation against cancer cells. Additionally, in hematologic malignancies, the inhibition of CXCR4 can mobilize hematopoietic stem cells and increase the availability of these cells for transplantation.
Indications and Uses
Balixafortide is being developed primarily for use in oncology and hematology, where its ability to modulate immune cell migration is expected to have significant therapeutic benefits. In cancer treatment, particularly for solid tumors and hematologic malignancies such as non-Hodgkin lymphoma and multiple myeloma, Balixafortide is investigated for its role in enhancing tumor-specific immune responses and overcoming immune evasion mechanisms. By blocking CXCR4, Balixafortide could potentially reverse tumor resistance to immunotherapy and improve the efficacy of chemotherapies and immune checkpoint inhibitors. In hematopoietic stem cell mobilization, Balixafortide is being explored as a therapeutic agent to facilitate stem cell collection for bone marrow transplants and cell therapies. This can be crucial for patients undergoing hematopoietic stem cell transplantation to ensure an adequate supply of stem cells for reconstitution of bone marrow after high-dose chemotherapy.
Efficacy and Clinical Benefits
In preclinical and early-phase clinical studies, Balixafortide has demonstrated the ability to effectively block CXCR4 signaling, which results in reduced tumor growth, metastasis, and immune suppression in animal models. Furthermore, in clinical trials, the peptide has shown potential in enhancing immune responses in patients receiving cancer immunotherapy, including checkpoint inhibitors. The peptide’s ability to mobilize hematopoietic stem cells has also been investigated, with promising results indicating that it can improve stem cell mobilization for transplantation procedures, which is critical for patients with hematological disorders. In combination with other therapeutic agents, Balixafortide may offer a synergistic effect, leading to better outcomes for cancer patients and those requiring stem cell transplants.
Safety and Tolerability
Preliminary data from clinical studies suggest that Balixafortide has a generally favorable safety profile, with most adverse effects being mild and transient. The most common side effects reported include injection site reactions and mild gastrointestinal symptoms. Since Balixafortide works by modulating the immune system, researchers are closely monitoring for potential issues such as overactivation of the immune system or increased risk of infections, which could occur with significant immune cell mobilization. However, so far, no major immune-related adverse events have been observed. As with any investigational drug, further studies are needed to assess its long-term safety and tolerability in larger patient populations and across diverse clinical indications.
Advantages and Limitations
The key advantage of Balixafortide is its ability to modulate immune cell trafficking by specifically targeting CXCR4, offering selective immune system modulation without the broad immunosuppressive effects of traditional therapies. This precision provides a high therapeutic index in cancer treatment and hematologic stem cell mobilization, where immune system activation is crucial for treatment success. However, its limitations include the need for injection-based administration, which may affect patient compliance, and the fact that its use is currently limited to oncology and hematology indications. Furthermore, as a relatively new agent, the long-term effects of blocking CXCR4 signaling in healthy immune function are not fully understood, necessitating further clinical investigation.
Future Directions
The future of Balixafortide is focused on expanding its applications in cancer immunotherapy, particularly in combination with checkpoint inhibitors and chemotherapy to enhance immune responses and overcome tumor resistance. Ongoing clinical trials are assessing its synergistic potential with other therapies, with the goal of improving patient outcomes in solid tumors and hematologic malignancies. In addition, further studies are exploring its use in hematopoietic stem cell mobilization for bone marrow transplants. As more data becomes available, Balixafortide may have broader applications in immune-based therapies for various cancers and in stem cell-based treatments for hematological disorders.
Reference:
Get a Quote
LinkPeptide
